62 results
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries
424B4
PCSA
Processa Pharmaceuticals Inc
29 Jan 24
Prospectus supplement with pricing info
4:15pm
responsibility for, and can provide no assurance as to the reliability of, any information that others may provide to you. This prospectus is not an offer to sell … activities.
Setting Executive Compensation
Our compensation committee has primary responsibility for, among other things, determining our
8-K
EX-3.1
ya4ujvc vn0
21 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:29pm
8-K
EX-10.1
50t1t1iaq30x081
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
z1csh
24 Mar 22
Prospectus supplement for primary offering
4:15pm
PRE 14A
qkoszgi84fr 91at
1 Sep 21
Preliminary proxy
4:46pm
424B5
hid zexh0wva2k
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-1.1
cc9 ujfox4
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
9gibzy 20iur
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am